Drug Type Universal CAR-T |
Synonyms IBI-345, IBI345 |
Target |
Action inhibitors |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Phase 1 | Switzerland | 30 Jan 2022 | |
| CLDN18.2 positive Solid Tumors | Phase 1 | China | 13 Dec 2021 |
Phase 1 | CLDN18.2 positive Solid Tumors CLDN18.2 positive | 5 | tocdwdocki(aykqjicbzr) = qxmjkyncjd cjoaivexbp (yutpmgtond ) | Positive | 23 Oct 2023 |





